Lorazepam linked to shorter progression-free survival in pancreatic cancer patients

Patients with pancreatic cancer who took the benzodiazepine lorazepam (Ativan), commonly prescribed to treat anxiety during cancer treatment, had a shorter progression-free survival than patients who did not, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

Related Keywords

United States ,American ,Michael Feigin ,Roswell Park ,Megan Craig ,Abigail Cornwell ,Roswell Park Alliance Foundation ,Clinical Cancer Research ,Cancer Research Foundation Inc ,American Association For Cancer Research ,Roswell Park Comprehensive Cancer Center ,American Association ,Cancer Research ,National Cancer Institute ,National Institutes ,Fifth District ,Research Foundation ,Cancer ,Lorazepam ,Pancreatic Cancer ,Anxiety ,Cancer Treatment ,Central Nervous System ,Chemotherapy ,Drugs ,Immunotherapy ,Insomnia ,Melanoma ,Neck ,Nervous System ,Rain ,Harmacology ,Prostate ,Research ,Herapeutics ,Humor ,Xanax ,